MARKET

CGIX

CGIX

CANCER GENETICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.890
-0.110
-2.75%
Closed 16:00 10/20 EDT
OPEN
4.050
PREV CLOSE
4.000
HIGH
4.050
LOW
3.810
VOLUME
38.14K
TURNOVER
--
52 WEEK HIGH
10.39
52 WEEK LOW
1.920
MARKET CAP
9.75M
P/E (TTM)
-1.0644
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Organovo Holdings, Lantern Pharma leads healthcare gainers, Fortress Biotech, Zynex among major losers
Gainers: Organovo Holdings (ONVO) +12%, Lantern Pharma (LTRN) +11%, Cancer Genetics (CGIX) +10%, American Well (AMWL) +10%, Immuron (IMRN) +9%.Losers: Avenue Therapeutics (ATXI) -57%, Zynex (ZYXI) -27%, Fortress Biotech (FBIO) -22%,  AgeX Therapeutics (AGE) -12%, Vaccinex (VCNX) -11%.
Seekingalpha · 10/12 14:58
Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference
RUTHERFORD, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced it will present at the 22nd Annual Rodman & Renshaw Global Investment Conference sponsored by H.C
GlobeNewswire · 09/10 13:00
Cancer Genetics and StemoniX Announce Joint Proof-of-Concept Program
RUTHERFORD, N.J., and MAPLE GROVE, MN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and StemoniX, Inc., a company empowering the discovery of new medicines through the convergence of novel human
GlobeNewswire · 09/03 12:00
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Cancer Genetics, Inc. - CGIX
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Cancer Genetics, Inc. ("Cancer Genetics" or the "Company") (Nasdaq: CGIX) relating to its merger with
PR Newswire · 08/31 16:36
MERGER ALERT CGIX, PRNB, and MNTA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / August 27, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
ACCESSWIRE · 08/27 17:45
Mid-Morning Market Update: Markets Mostly Lower; Hormel Foods Earnings Top Views
Following the market opening Tuesday, the Dow traded down 0.24% to 28240.82 while the NASDAQ rose 0.01% to 11378.17. However, the S&P fell 0.02% to 3431.91.
Benzinga · 08/25 15:59
Company News for Aug 25, 2020
Companies in the news are: ZM, AXAS, CGIX, BWAY
Zacks · 08/25 15:21
iBio and Viveve Medical among healthcare gainers; Proteostasis Therapeutics among losers
Gainers: Viveve Medical (VIVE) +113%. Orchard Therapeutics (ORTX) +27%. iBio (IBIO) +16%. Idera Pharmaceuticals (IDRA) +15%. Cutera (CUTR) +14%.Losers: Sonnet BioTherapeutics (SONN) -21%. Cancer Genetics (CGIX) -17%. Liminal BioSciences (LMNL) -16%. Proteostasis Therapeutics (PTI) -15%. Lipocine
Seekingalpha · 08/25 15:06
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CGIX. Analyze the recent business situations of CANCER GENETICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CGIX stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 3.79M
% Owned: 151.19%
Shares Outstanding: 2.51M
TypeInstitutionsShares
Increased
1
12.56K
New
5
1.88K
Decreased
4
1.83K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+0.47%
Healthcare Providers & Services
+0.06%
Key Executives
Non-Executive Chairman
John Pappajohn
President/Chief Executive Officer
John Roberts
Chief Financial Officer
Glenn Miles
Vice President - Research & Development
Jane Houldsworth
Director
Geoffrey Harris
Director
Thomas Widmann
Independent Director
Edmund Cannon
Independent Director
Howard McLeod
Independent Director
Franklyn Prendergast
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CGIX
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. Through its subsidiary, the Company offers preclinical test systems. The Company offers discovery services to the pharmaceutical industry, biotechnology companies and academic research centers. The Company provides the tools and testing methods for companies and researchers to identify new molecular- and biomarker-based indicators for disease and to determine the pharmacogenomics, toxicity and efficacy of therapeutic candidate compounds. Its discovery services include development of both xenograft and syngeneic animal models, toxicology and genetic toxicology services, pharmacology testing, pathology services, and validation of biomarkers for diseases including cancers. It also provides consulting, guidance and preparation of samples.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cancer Genetics Inc stock information, including NASDAQ:CGIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CGIX stock methods without spending real money on the virtual paper trading platform.